Posted by Michael Wonder on 28 Oct 2024
Fasenra approved in the EU for eosinophilic granulomatosis with polyangiitis
28 October 2024 - New indication supported by the MANDARA trial, which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroids
AstraZeneca’s Fasenra (benralizumab) has been approved in the European Union as an add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis.
